



# FAOPS

## 2025

The 24th Congress  
of the Federation of  
Asia and Oceania  
Perinatal Societies

*Innovation and Integration: Shaping the future of  
Perinatal Care in Asia and Oceania*

## ABSTRACT BOOK

NOVEMBER 14-16, 2025  
KATHMANDU, NEPAL



[www.faops2025.org](http://www.faops2025.org)



**FAOPS**  
Federation of Asia and  
Oceania Perinatal  
Societies



**PESON**  
Perinatal  
Society of Nepal

# 24th Congress of FAOPS 2025

## Organizing Committee



**Prof. Dr. Ashma Rana**  
Organizing Chairperson,



**Prof. Dr. Sunil Raja  
Manandhar**  
Organizing  
Co-Chairperson



**Dr. Bina Basnyat**  
Organizing Secretary



**Prof. Dr. Kalpana  
Upadhyay Subedi**  
Scientific Committee  
Chairperson



**Dr. Shailendra Bir  
Karmacharya**  
International/National  
Correlation, Chairperson



**Dr. Sushila Shrestha**  
Registration Committee  
Chairperson



**Prof. Dr. Heera Tuladhar**  
Treasurer



**Dr. Bimala Malla**  
Hospitality Reception & Cultural  
Program Committee  
Chairperson



**Dr. Shailendra Bir  
Karmacharya**  
Souvenir Committee, Chairperson



# म्यालि हस्पिटल प्रा. लि.

## Valley Hospital Pvt. Ltd.

Putalisadak, kathmandu | Phone: 01-4520224, 4513091

हामी काठमाडौंको पुतलीसडकमा रहेर यहाँहरु  
माझ उत्कृष्ट, विश्वसनीय र मितव्यायि स्वास्थ्य  
सेवा प्रदान गर्ने प्रतिबद्ध छौं।

### Our Medical Personalities



**Dr. Bina**

Consultant  
Obstetric & Gynecology



**Dr. Bimala**

Consultant  
Obstetric & Gynecology



**Prof. Dr. Chanda**

Consultant  
Obstetric & Gynecology



**Dr. Sudha**

Consultant  
Obstetric & Gynecology



**Prof. Dr. Saraswati**

Consultant  
Obstetric & Gynecology



**Dr. Amila**

Consultant  
Obstetric & Gynecology



**Dr. Raviyalaxmi**

Consultant  
Obstetric & Gynecology



**Dr. Ganesh**

Consultant  
Obstetric & Gynecology



**Dr. Durga**

Consultant  
Obstetric & Gynecology



**Dr. Sushila**

Consultant  
Obstetric & Gynecology



**Prof. Dr. Mukund**

General Surgeon



**Dr. Keshari**

Consultant  
Obstetric & Gynecology



**Dr. Sutap**

Cardiologist



**Dr. Manish**

Consultant  
Paediatric Surgeon



**Dr. Shailendra**

Consultant  
Pediatrician



**Dr. Deep**

Consultant ENT-HNS



**Dr. Rumina**

Consultant  
Obstetric & Gynecology



**Dr. Chanda**

Consultant Physician  
Internal Medicine



**Dr. Manish**

Consultant  
General Surgery



**Dr. Preksha**

Consultant  
Obstetric & Gynecology



**Dr. Sabina**

Consultant  
Dermatologist

### Our Medical Services

- ✓ Obstetrics & Gynecology
- ✓ Pediatric
- ✓ General Medicine
- ✓ General Surgery
- ✓ Ear, Nose and Throat
- ✓ Vaccinations
- ✓ Menopausal Clinic
- ✓ Infertility Clinic
- ✓ USG
- ✓ Dermatology
- ✓ Cardiology
- ✓ Psychiatric
- ✓ Endocrinology
- ✓ Orthopaedic
- ✓ Neurology
- ✓ Pathology
- ✓ Pharmacy
- ✓ Ambulance



01-4520224, 9864150673



Putalisadak, Kathmandu



valleyhospital.pvtltd@gmail.com



Abbott

For the use of a Registered Medical Practitioner or a Hospital or a Laboratory only.

The most advanced, 3<sup>rd</sup> generation, subunit quadrivalent Influenza vaccine<sup>1-3</sup>

# INFLUVAC<sup>®</sup> TETRA

Influenza vaccine (surface antigen, inactivated)

*More Power with Broad Protection<sup>†</sup>*



Most advanced, **3<sup>rd</sup> generation**,  
subunit quadrivalent Influenza vaccine  
with less impurities<sup>1-4</sup>



**Prefilled syringe**, ready to use  
and convenient<sup>4</sup>



Images shown are not of actual patients and are for representational purpose only

<sup>1</sup> Vesikari T, et al. Int J Infect Dis. 2020;92:29-37

<sup>2</sup> Centers for Disease Control and Prevention. Quadrivalent Influenza Vaccine. [Internet]. [Updated 2019 Nov 6] [Cited 2023 Jan 16]. Available at: <https://www.cdc.gov/flu/prevent/quadrivalent.htm>

<sup>3</sup> Shah R, et al. Advantages of Subunit Influenza Vaccine: An Overall Perspective. AJP. 2018; (15): 19-28. <sup>4</sup> Wood JM, Williams MS. History of inactivated Influenza vaccines. In: textbook of influenza. Oxford: Blackwell Science 1998, pp. 317-323. <sup>5</sup> Influvac Tetra PI, Data on file

Abbreviated Prescribing Information Inactivated Influenza Vaccine (Surface Antigen) IP Influvac 2021 (Suspension for injection) Composition: Influenza virus surface antigens (haemagglutinin and neuraminidase) of the following strains<sup>6</sup>: A/Victoria/2570/2019 (H1N1)pdm09-like strain/A/Victoria/2570/2019 (IVR-215) 15 micrograms HA<sup>7</sup> A/Hong Kong/267/2019 (H3N2)-like strain (A/Hong Kong/267/2019, IVR-208) 15 micrograms HA<sup>7</sup> B/Washington/02/2019-like strain (B/Washington/02/2019, wild type) 15 micrograms HA<sup>7</sup> propagated in fertilized chicken eggs. Influvac 2021 is indicated for the prevention and treatment of the acute seasonal influenza. Prophylactic use in healthy individuals, especially those who run an increased risk of associated complications. Influvac 2021 is indicated in adults and children from 6 months of age. Vaccination is particularly recommended for the following categories of patients: children aged ≥ 65 yrs, regardless of their health condition, adults and children with chronic disorders of the pulmonary or cardiovascular systems, including asthma, adults and children with chronic metabolic diseases such as diabetes mellitus, adults and children with chronic renal dysfunction, adults and children with immunodeficiencies due to disease or immunosuppressant medication (e.g., cytostatics or corticosteroids) or radiotherapy, children and teenagers (6 months<sup>8</sup> - 18 years) who receive long-term acetylsalicylic acid containing medication, and might therefore be at risk for developing Reyes syndrome following an influenza infection. Dosage and administration: Adults: 0.5 ml. Paediatric population Children from 36 months<sup>8</sup> onwards: 0.5 ml. Children from 6 months<sup>8</sup> to 35 months<sup>8</sup>: Clinical data are limited; doses of 0.25 ml or 0.5 ml may be given. For children who have not previously been immunised, the first dose should be given at a lower dose (0.25 ml) and the second dose at least 4 weeks later. For children aged 6 months<sup>8</sup> to 35 months<sup>8</sup> who have previously been immunised, the dose should be 0.5 ml. The dose should be given as an intramuscular or deep subcutaneous injection. Contraindications: Hypersensitivity to the active substance and to any of the excipients or to any component that may be present as traces such as eggs (ovalbumin, chicken proteins), formaldehyde, cetyltrimethylammonium bromide, polyisobutylene 80 or gentamicin. Immunization shall be postponed in patients/children with febrile illness or acute infection. Warnings and Precautions: As with all injectable vaccines, appropriate medical treatment and supervision should always be readily available in case of an anaphylactic event following the administration of the vaccine. Influvac 2019-20 should under no circumstances be administered intra-ocularly. Antibody response in patients/children with endogenous or iatrogenic immunosuppression may be insufficient. Pregnancy and lactation: Inactivated influenza vaccines can be used in all stages of pregnancy. Larger datasets on safety are available for the second and third trimester, compared with the first trimester; however, data from worldwide use of influenza vaccine do not indicate any adverse fetal and maternal effects attributable to the use of the vaccine during pregnancy. Contraindications: Hypersensitivity to any of the excipients. Adverse reactions: Local: pain, redness, swelling, induration. These reactions usually disappear within 1-2 days without treatment. Other common adverse effects observed are myalgia, fever, malaise, shivering and fatigue. Adverse reactions reported from post marketing surveillance are, next to the reactions which have also been observed during the clinical trials include transient thrombocytopenia, transient lymphadenopathy, allergic reactions, in rare cases leading to shock, anaphylaxis, urticaria, paresthesia, febrile convulsions, neurological disorders, such as encephalomyelitis, neuritis and Guillain-Barré syndrome. Vasculitis associated in very rare cases with transient renal involvement. Generalised skin reactions including pruritus, urticaria or non-specific rash. Issued on: Source: Prepared based on full prescribing information dated May 2019. ©Trademark of the Abbott Biologics B.V., The Netherlands. For full prescribing information, please contact: Abbott India Ltd., Medical Services Division, Floor 16, Godrej BKC, Plot No.: C-68, Near MCA Club, Bandra (E), Mumbai - 400051.